Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 10, 2024

Efficacy and Safety of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis of the Scalp

Journal of the American Academy of Dermatology

 

Additional Info

Journal of the American Academy of Dermatology
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study
J Am Acad Dermatol 2024 Mar 28;[EPub Ahead of Print], K Gebauer, L Spelman, PS Yamauchi, J Bagel, T Nishandar, M Crane, I Kopeloff, M Kothekar, SL Yao, HL Sofen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading